Current evidence is limited by few studies and short follow-up; large-scale randomized controlled trials with dementia as a primary endpoint, head-to-head drug class comparisons, and inclusion of long-term care residents-who bear the highest disease burden yet are underrepresented in trials-are urgently needed to inform precision prescribing guidelines.
Ding et al. (Tue,) studied this question.